Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
Thursday, May 1st, was a busy day at the FDA, and the pattern that emerges is straightforward: the agency approved a lot of drugs, most of them versions of medicines that already exist. That might sound routine, but it points to something worth noticing if you're in the business of making drugs or the companies that support them.
The approvals broke into two kinds. One batch was generic versions of established treatments: propranolol hydrochloride (a blood pressure drug), torsemide (a diuretic), mirabegron (for overactive bladder), methotrexate sodium (used in cancer and autoimmune disease), fluvoxamine maleate (an antidepressant), and fluorescein sodium (a dye used to image the eye). These are drugs that have been around, and now other manufacturers can make them. That tends to expand who can supply them and at what price, which matters for the clinics and hospitals that buy them, but it also means more work for the companies that handle manufacturing, quality testing, and the paperwork that comes with a new maker entering the market.
The other kind was new formulations of drugs already on the market. Incyte got approval for an extended-release version of Jakafi, a drug used in certain blood cancers and bone marrow disorders. Apotex got approval for a new formulation of Evdi. These kinds of changes, where a company reformulates an existing drug or shifts manufacturing to a new site, tend to pull in the specialists who handle process development and the analytical work that proves the new version works the same way as the old one.
Arvinas Operations got approval for Veppanu, which is a new molecular entity, meaning it's a drug that hasn't been approved before anywhere. It's a single approval among a lot of generics and reformulations, but new drugs like this tend to signal where companies are betting on emerging therapeutic areas. They also tend to drive demand for the specialized manufacturing expertise and regulatory support that comes with bringing something genuinely novel to market. We only see what we happen to pick up, so treat this as a few signals, not the whole board. Still, this week leaned heavily toward the manufacturers and the service providers who support them.
Separately, PPD Development, a company that runs clinical trials, received an 8.96 million dollar grant from the National Institute of Allergy and Infectious Diseases to coordinate a large transplantation research program. Government funding like this tends to sustain the infrastructure that keeps trials running.